Department of EthicsPlacebo-controlled trials and the Declaration of Helsinki
Section snippets
Revised Declaration of Helsinki
The Declaration of Helsinki, first drawn up in 1964, has become standard guidance for all medical research that involves human beings. In particular, it has been widely used to guide the conduct of clinical trials done to develop new medicinal products. The revision of the declaration,1 issued by the World Medical Association in October, 2000, has been appropriately strengthened in several areas and its relevance and value remains as great as ever. However, the new version contains one section,
Clinical trials of new medicinal products
A wide variety of clinical trials are done during the development of a new product, in healthy individuals and in patients. The trials that could be affected by section 29 are done in phase III, and sometimes the later part of phase II. They are the trials done in patients with the target disease to provide pivotal evidence of efficacy. In such trials, the product should generally be tested in the planned manner of use in the intended population. Hence medical research is combined with medical
Advantages of placebo-controlled trials
There are well known reasons why placebo-controlled trials are generally more reliable than active-controlled trials in provision of conclusive proof of efficacy. The reasons are fully discussed in the E10 guideline Choice of Control Group,8 which was produced under the auspices of the International Conference on Harmonisation (ICH) and has been adopted in Europe, USA, and Japan. Other guidelines and publications also refer to this issue.9, 10, 11
Briefly, placebo-controlled trials provide their
Improvement over an active control
Some active-controlled trials have similar methodological strengths, namely those aiming to show the improved efficacy of the test product. Showing that a test product has improved efficacy compared with an already licensed product is clearly a satisfactory result, and has the same reassurance with respect to the internal validity of the trial. However, it is noteworthy that in comparative clinical trials many potentially valuable new medicinal products do not have greater efficacy than
Similar efficacy to an active control
The methodological difficulty that results in the continuing need for placebo-controlled trials relates to active-controlled trials intended to show that two treatments have similar effects. Similarity is a far more likely objective in practical situations, in which active controls might be considered. Such trials are often set up as non-inferiority trials rather than equivalence trials. In these studies, similarity or superiority to the active control are both regarded as satisfactory
Designs that reduce exposure to placebo
Even in a straightforward placebo-controlled trial, receiving placebo does not imply receiving no medical treatment. In most trials there will be other medications that are permitted in both treatment groups and that are expected to be used to a roughly similar extent. Rescue medication will be predefined, when appropriate, for use in circumstances described in the protocol. Additionally, a standard condition in all clinical trials is that at any stage patients can withdraw, either from
Ethically acceptable use of placebo control
Although alternative designs are always available, they often do not provide satisfactory answers. Straightforward randomised placebo-controlled comparisons are generally scientifically desirable for reliable evidence of efficacy, even when active treatments are already in widespread use. In what circumstances can such trials be ethically done?
In this connection it is important to draw a distinction between signs and symptoms that the patient could have without any irreversible harm, those that
Conclusion
Although our view of the ethicality of placebo might seem inconsistent with the meaning of section 29 of the declaration, it echos widely held opinions.16, 17 There are several areas of medicine in which licensed products are available, but in which placebo-controlled trials still remain the only means of conclusively assessing the efficacy of new medicinal products whose potential advantages lie in areas other than efficacy. Provided that the safety and interests of individual patients are
References (17)
- et al.
Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study
Eur J Neuropsychopharmacol
(2001) - et al.
Beta blockade during and after myocardial infarction: an overview of the randomised trials
Prog Cardiovasc Dis
(1985) Declaration of Helsinki (as revised)
Doctors revise Declaration of Helsinki
BMJ
(2000)- et al.
Ethical issues in the design and conduct of clinical trials in developing countries
N Engl J Med
(2001) - et al.
Research involving human subjects in developing countries
N Engl J Med
(2001) Placebos on trial
Ann Neurol
(2001)- et al.
The continued unethical use of placebo controls
N Engl J Med
(1994)
Cited by (82)
Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks
2024, Schizophrenia ResearchEthical Considerations When Preparing a Clinical Research Protocol
2020, Ethical Considerations When Preparing a Clinical Research ProtocolShould fast breathing pneumonia cases be treated with antibiotics? The scientific rationale for revisiting management in Low and Middle income countries
2019, International Journal of Infectious DiseasesCitation Excerpt :Moreover, these trials must be designed in such a way that continued surveillance and easy re-access to health facilities is feasible and that rescue treatment introduction possible in case of deterioration and failure of expected resolution. ( Lewis et al., 2002). Such trials should be blinded and randomized to reduce potential bias and enhance the quality and generalizability of study results, considered the “most important design techniques for avoiding bias in clinical trials” (International Conference on Harmonisation EEWG, 1999).
A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics
2016, Multiple Sclerosis and Related DisordersCitation Excerpt :The Declaration of Helsinki, adopted by the World Medical Association in 1964 and updated periodically, is one of the most influential international standards guiding medical research with human subjects (Carlson et al., 2004; Forster et al., 2001; Hellmann et al., 2014; Millum et al., 2013). Its revision in 2000 (Lewis et al., 2002) specifically addressed the ethics of PCTs in an era of available therapy and stating “the risks, benefits, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic and therapeutic methods. This does not exclude the use of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic method exists” (Lewis et al., 2002).
Designing robust clinical trials for orphan drugs
2013, Orphan drugs: Understanding the rare disease market and its dynamics